KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer

Biomark Med. 2024;18(10-12):511. doi: 10.1080/17520363.2024.2352421. Epub 2024 Aug 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Drug Resistance, Neoplasm* / drug effects
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local*
  • Ovarian Neoplasms* / drug therapy
  • Platinum / therapeutic use
  • Prognosis
  • Treatment Outcome

Substances

  • Platinum